Biotech suppliers face a unique financial challenge: managing million-dollar research equipment purchases, navigating complex compliance requirements for clinical trial payments, and coordinating transactions across international research collaborations—all while maintaining cash flow for critical R&D operations. The global biotechnology industry, growing at approximately 12.67% annually and valued at over $2.42 trillion, demands payment platforms that understand high-value transactions, regulatory complexity, and cross-border operations. For biotech suppliers looking to streamline their financial operations while enhancing buyer purchasing power, solutions like Resolve's B2B Net Terms provide the embedded credit expertise needed to offer flexible payment options without sacrificing cash flow.
ResolvePay offers biotech suppliers a comprehensive solution that combines embedded credit expertise, accounts receivable automation, and non-recourse invoice advancement into a unified platform specifically designed for B2B transactions.
ResolvePay enables biotech suppliers to offer net payment terms to their customers—research institutions, hospitals, and pharmaceutical companies—without taking on the credit risk or cash flow disruption. This is particularly valuable in biotech where customers often require extended payment terms but suppliers need immediate cash flow for R&D and operations. The platform acts as your complete credit team, handling everything from initial credit assessment through final collections while you focus on core business activities.
The non-recourse financing model means ResolvePay assumes the majority risk of late payments or defaults, protecting your business from bad debt while enabling you to offer competitive payment terms that drive sales growth. This approach transforms extended payment terms from a cash flow liability into a strategic competitive advantage.
ResolvePay distinguishes itself by offering true embedded credit—not just payment processing. The platform becomes your outsourced credit department, bringing enterprise-level credit expertise to businesses of any size. This is especially valuable for biotech suppliers who need to compete with larger companies that can afford to offer extended terms but lack the resources to manage credit risk internally.
The platform's Net Terms Management solution enables suppliers to increase average order values and win larger contracts by offering payment flexibility that research institutions and healthcare organizations require. By receiving immediate payment while buyers get extended terms, suppliers eliminate the traditional trade-off between cash flow and competitive payment options.
Biotech suppliers are looking to increase sales by offering flexible payment terms while protecting cash flow, reducing administrative overhead, and eliminating credit risk through non-recourse financing.
Vellis Financial is a payment platform explicitly designed for the biotechnology sector, offering industry-specific compliance and multi-currency capabilities essential for global research operations. Vellis addresses the unique regulatory landscape biotech suppliers navigate, providing PCI-DSS Level 1 certification and HIPAA compliance out-of-the-box. This is critical for suppliers handling sensitive clinical data or processing payments related to patient care. The platform specializes across key biotech verticals including pharmaceutical research, genomics, biomanufacturing, and medical devices.
Biotech suppliers require specialized compliance infrastructure and multi-currency support for cross-border research partnerships and high-value equipment sales.
QuadraPay has established itself as a specialist in biotech payment processing since 2016. QuadraPay reports being cited across multiple major international payment industry research reports. QuadraPay understands that biotech transactions often involve complex compliance across multiple jurisdictions and high-value payments for research funding, international supplier arrangements, and specialized equipment. The platform specializes in biotech subsectors including nutraceuticals, diagnostics, peptides, and supplements.
Biotech suppliers in specialized subsectors requiring dedicated payment processing capabilities.
Tipalti excels at managing complex global payment operations, making it ideal for biotech companies with extensive international vendor networks including CROs, research labs, and clinical trial sites across multiple countries. Tipalti's strength lies in its comprehensive compliance automation, handling W-8/W-9 collection, 1099 reporting, and international tax requirements that are critical for biotech companies operating across borders.
Companies have achieved significant efficiency gains using Tipalti's platform, with documented 80% reduction in AP processing time. Mid-to-large biotech companies managing complex international vendor payments and requiring robust compliance automation.
Billtrust brings specialized expertise from the healthcare and medical supply sector, directly applicable to biotech suppliers. The platform understands the unique challenges of high-value transactions common in healthcare-related industries. Billtrust recognizes that medical and biotech payments can average significantly higher than typical B2B transactions—often exceeding $100,000—requiring specialized handling and compliance. The platform automates complex payment scenarios while maintaining HIPAA compliance.
Biotech suppliers selling to healthcare institutions, hospitals, and research organizations requiring specialized AR automation.
HighRadius offers comprehensive AR automation for large biotech and pharmaceutical enterprises, processing substantial transaction volumes with Fortune 500 clients including Sanofi. HighRadius leverages AI and machine learning to automate complex AR processes, achieving high straight-through processing rates for cash application. This is particularly valuable for large biotech companies managing receivables from multiple healthcare providers, distributors, and international customers.
HighRadius processes over $1T in transactions annually with high cash application accuracy rates. Large biotech and pharmaceutical enterprises require enterprise-grade AR automation with proven scalability.
Airwallex specializes in cross-border payments with competitive foreign exchange rates, making it ideal for biotech companies with international research operations, global supplier networks, or customers across multiple countries. Airwallex holds regulatory licenses across Australia, Singapore, Hong Kong, Japan, UK, US, Canada, and EU, ensuring compliant international operations. The platform offers competitive interbank FX rates, crucial for biotech companies making frequent high-value international payments.
Biotech companies with frequent cross-border payments requiring cost-effective international transfers and multi-currency accounts.
Stripe provides flexible payment infrastructure for biotech companies that need to build custom payment workflows integrated with lab management systems, research databases, or proprietary platforms. Stripe's advanced APIs and extensive documentation make it suitable for developers building sophisticated biotech payment solutions. The platform scales from startup biotech companies to enterprise pharmaceutical operations.
Biotech companies with development resources needing to build custom payment integrations or requiring flexibility in their payment infrastructure.
Rillion offers comprehensive AP automation with healthcare vertical experience, directly applicable to biotech suppliers. The platform serves thousands of companies across healthcare, manufacturing, and hospitality sectors. Rillion's experience with healthcare payment complexity translates well to biotech supplier needs. The platform handles multi-entity management critical for biotech companies with research labs, manufacturing facilities, and offices across multiple locations.
Rillion serves thousands of companies with strong invoice capture accuracy. Mid-market biotech companies require robust AP automation with healthcare industry experience and multi-entity capabilities.
Flywire brings expertise from the healthcare and education sectors, making it well-suited for biotech suppliers selling to hospitals, research institutions, universities, and medical facilities. Flywire's strength lies in its ability to embed within existing A/R workflows for healthcare and education clients. This vertical-specific approach ensures integration with the complex payment systems used by research institutions and healthcare providers.
Biotech suppliers whose primary customers are hospitals, research institutions, universities, and other healthcare or educational organizations.
Bill.com offers accessible AP/AR automation for early-stage and small biotech companies needing to automate supplier payments without enterprise-level complexity. Bill.com's simple interface and extensive vendor network make it suitable for smaller biotech companies beginning to scale their operations. The platform's substantial vendor network means many lab suppliers are likely already in the system.
Early-stage and small biotech companies needing affordable, simple payment automation.
Wise Business provides cost-effective solutions for small-to-mid biotech companies making frequent international payments to suppliers, CROs, or research partners. Wise Business offers transparent pricing, displaying real mid-market exchange rates upfront. This transparency is valuable for biotech companies operating on research budgets.
Small-to-mid biotech companies making frequent international payments who prioritize transparent pricing and cost-effectiveness.
Selecting the right payment platform depends on your specific operational needs, growth stage, and strategic objectives. For biotech suppliers looking to increase sales by offering net payment terms while protecting cash flow, ResolvePay's comprehensive Net Terms Management solution provides the embedded credit expertise, non-recourse financing, and AR automation needed to compete effectively without taking on credit risk.
Company Size and Complexity: Large biotech enterprises with complex global operations may benefit from enterprise-grade automation platforms like HighRadius or Tipalti. Mid-market companies often find balanced capabilities in platforms like Rillion or ResolvePay. Small biotech startups may prefer accessible options like Bill.com or Wise Business.
Compliance Requirements: Suppliers handling sensitive health data or clinical trial payments require HIPAA-compliant platforms like Vellis Financial, Billtrust, or ResolvePay's Business Credit Check services that handle compliance requirements appropriately.
Global Operations: Companies with international research collaborations or supplier networks should prioritize platforms with strong multi-currency support like Airwallex, Vellis Financial, or Wise Business.
Credit Terms Strategy: Biotech suppliers looking to win larger contracts and increase average order values by offering net payment terms should consider ResolvePay's approach, which provides non-recourse financing while handling credit assessment and collections, eliminating the traditional trade-off between competitive payment terms and cash flow protection.
Integration Needs: Ensure your chosen platform integrates with your existing ERP, accounting, and commerce systems. ResolvePay offers extensive integrations with platforms like QuickBooks, Oracle, Shopify, and Magento for seamless financial operations.
Biotech suppliers can turn payment terms into a growth driver with ResolvePay’s embedded credit model. You can offer the flexible terms research institutions and healthcare buyers expect while getting paid immediately and removing credit risk through non-recourse financing. AI-powered credit decisions analyze thousands of data points to deliver instant approvals for purchases up to $25,000, keeping sales moving while maintaining rigorous risk standards.
ResolvePay advances up to 100% of approved invoice value within 24 hours, supporting working capital for critical R&D operations and equipment needs. It also functions as your outsourced credit team—managing credit assessment through collections—so you don’t need to build an internal department to compete with larger suppliers. The accounts receivable automation streamlines invoicing, collection, and reconciliation to reduce DSO. A white-label portal preserves your brand and accepts ACH, wire, card, and check, with ERP/accounting integrations to keep data synced.
Specialized B2B platforms fit biotech needs: high-value orders (often $100K+), HIPAA/PCI-DSS compliance, and international payments. They add automated compliance handling, multi-currency support, and biotech workflows, plus net terms with immediate payment via non-recourse financing.
Net terms boost buyer purchasing power so institutions can place larger orders without upfront cash. That flexibility helps you win deals from bigger competitors. ResolvePay lets you offer net terms while receiving immediate payment through non-recourse financing.
Payment processors only authorize and settle transactions. Comprehensive B2B platforms manage credit assessment, AR automation, compliance, and global payments end to end. For biotech, full platforms are usually better because they support complex, high-value, regulated sales.
Yes. Many platforms integrate with ERPs and accounting tools to sync invoices, payments, and reconciliation automatically. ResolvePay connects with accounting, and commerce platforms like QuickBooks, Oracle, Shopify, and Magento to reduce manual entry and errors.
Non-recourse advancement means the platform takes customer non-payment risk—if the buyer doesn’t pay, you keep the funds. ResolvePay offers non-recourse financing, advancing up to 90% within 24 hours, protecting cash flow and reducing bad debt.
This post is to be used for informational purposes only and does not constitute formal legal, business, or tax advice. Each person should consult his or her own attorney, business advisor, or tax advisor with respect to matters referenced in this post. Resolve assumes no liability for actions taken in reliance upon the information contained herein.